Clinical Trials Browser

Phase 1 × Terminated × Hematologic Diseases × Clear all

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT02978235 2024-09-05

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Phase 1 Terminated

11 enrolled

LymphoidPlasma cell

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Phase 1 Terminated

4 enrolled

Plasma cell

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT02452983 2022-06-02

SS1

Phase 1 Terminated

14 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Preleukemia

NCT02641002 2018-10-18

A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Phase 1 Terminated

28 enrolled

MyeloidOther hematologic neoplasm

Hematologic Diseases, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00649584 2014-12-18

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

Phase 1 Terminated

44 enrolled

Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

Clinical Trials

CYNK001AML01

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

SS1

A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies